Astra Nova and ACRES Partner on Quality and Access of Training for Research Professionals
Astra Nova Training and ACRES announced a strategic alliance collaboration
Astra Nova Training, a global provider of consultancy and pharma training services, and the Alliance for Clinical Research Excellence and Safety (ACRES), a non-profit integrating the expertise and investments of research stakeholders world-wide to build and maintain a global system for clinical trials, announced a strategic alliance collaboration to improve the expertise of industry professionals through improved and easily available training quality.
UK-based Astra Nova has introduced an international network of over 140 industry experts, as well as over 20 free and commercial online training courses, accessible on their Learning Management System. More than 5,000 professionals worldwide have obtained industry certification through their in-house and online training solutions. Astra Nova, with a strong commitment to corporate social responsibility, will make available interactive and easy-to access online training solutions for ACRES Global Platform of services.
With Astra Nova, ACRES will provide timely information on critical training topics and materials needed globally and they will partner on Learning Management Systems development. Other collaborative efforts involve jointly organizing multi-stakeholder events dedicated to improving the conduct of clinical research globally.
Read the full release here.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
